Clinical Trial Update: Study of the Glutaminase Inhibitor CB-839 in Leukemia [Phase 1]

View source ↗

Summary

This document provides a Phase 1 trial update for CB-839, a glutaminase inhibitor, in patients with acute myeloid leukemia and acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• CB-839 (telaglenastat)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Phase 1 | Status: COMPLETED